Insmed (INSM) News Today → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Free INSM Stock Alerts $53.55 +5.49 (+11.42%) (As of 04:00 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29 at 1:30 PM | marketwatch.comInsmed Shares Extend Gains, Reach 23-Year HighMay 29 at 1:30 PM | finance.yahoo.comInsmed PT Raised to $67 at TD CowenMay 29 at 12:47 PM | marketbeat.comInsmed (NASDAQ:INSM) Shares Gap Down to $48.06Insmed (NASDAQ:INSM) Shares Gap Down to $48.06May 29 at 11:27 AM | marketbeat.comInsmed (NASDAQ:INSM) Price Target Raised to $67.00 at TD CowenTD Cowen upped their target price on shares of Insmed from $45.00 to $67.00 and gave the company a "buy" rating in a research note on Wednesday.May 29 at 8:30 AM | msn.comInsmed’s stock should triple after positive drug trial data, analyst saysMay 29 at 2:56 AM | americanbankingnews.comBank of America Reaffirms Buy Rating for Insmed (NASDAQ:INSM)May 29 at 1:17 AM | markets.businessinsider.comBuy Rating on Insmed: Anticipating Growth and Increased Stock ValueMay 29 at 1:17 AM | markets.businessinsider.comInsmed’s Promising Future: A Buy Rating with Increased Price Target Post-ASPEN Trial SuccessMay 28 at 8:16 PM | finance.yahoo.comInsmed stock blasts off over lung condition study resultsMay 28 at 8:16 PM | msn.comInsmed Stock More Than Doubled in Value Tuesday—Here’s WhyMay 28 at 6:21 PM | prnewswire.comInsmed Announces Proposed $500 Million Public Offering of Common StockMay 28 at 5:25 PM | investopedia.comInsmed Stock More Than Doubled in Value Tuesday—Here's WhyMay 28 at 3:16 PM | finance.yahoo.comInsmed Shares Rocket After Drug Eases Lung Disease SymptomsMay 28 at 3:16 PM | seekingalpha.comInsmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)May 28 at 3:16 PM | msn.comInsmed Stock More Than Doubles on Trial Win for Lung-Condition DrugMay 28 at 3:16 PM | finance.yahoo.comInsmed Stock Surges on Trial Win for Lung-Condition Drug. ‘We Hit the Mark,’ CEO Says.May 28 at 1:20 PM | marketbeat.comInsmed (NASDAQ:INSM) Receives Buy Rating from Bank of AmericaBank of America reaffirmed a "buy" rating and issued a $40.00 target price on shares of Insmed in a report on Tuesday.May 28 at 12:36 PM | proactiveinvestors.comInsmed shares skyrocket on positive trial results for lung drugMay 28 at 12:21 PM | marketbeat.comInsmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024Stocks that are trading heavily or have substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fallMay 28 at 10:39 AM | marketbeat.comInsmed (NASDAQ:INSM) Hits New 52-Week High at $50.10Insmed (NASDAQ:INSM) Sets New 52-Week High at $50.10May 28 at 8:40 AM | investorplace.comWhy Is Insmed (INSM) Stock Up 134% Today?May 28 at 8:32 AM | marketwatch.comInsmed Shares Double on Positive Results for Brensocatib TrialMay 28 at 8:32 AM | msn.comInsmed surges on late-stage win for lung disease therapyMay 28 at 8:32 AM | markets.businessinsider.comInsmed Reports Positive Topline Results From ASPEN Study Of Brensocatib; Plans To File NDAMay 28 at 8:32 AM | finance.yahoo.comInsmed Shares Surge After Drug Eases Lung Disease SymptomsMay 28 at 6:54 AM | reuters.comInsmed's lung disease drug succeeds in late-stage studyMay 28 at 6:30 AM | prnewswire.comInsmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with BronchiectasisMay 27 at 9:02 PM | finance.yahoo.comIs Insmed Incorporated (NASDAQ:INSM) a Buy According to Hedge Funds?May 27 at 4:00 PM | prnewswire.comInsmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with BronchiectasisMay 27 at 1:37 AM | marketbeat.comInsmed Incorporated (NASDAQ:INSM) Given Average Rating of "Buy" by AnalystsInsmed Incorporated (NASDAQ:INSM - Get Free Report) has received a consensus recommendation of "Buy" from the fourteen brokerages that are presently covering the company, MarketBeat.com reports. Fourteen analysts have rated the stock with a buy rating. The average 1-year target price among brokersMay 26 at 5:20 AM | americanbankingnews.comInsmed (NASDAQ:INSM) Stock Price Down 2.8%May 24, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Trading Down 2.8%Insmed (NASDAQ:INSM) Stock Price Down 2.8%May 24, 2024 | marketbeat.comTrexquant Investment LP Cuts Stake in Insmed Incorporated (NASDAQ:INSM)Trexquant Investment LP cut its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 64.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,482 shares of the biopharmaceutical company's stockMay 21, 2024 | benzinga.comInsmed Unusual Options Activity For May 21May 21, 2024 | marketbeat.comGW&K Investment Management LLC Sells 60,497 Shares of Insmed Incorporated (NASDAQ:INSM)GW&K Investment Management LLC lessened its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 4.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,291,772 shares of the biopharmaceutical company'sMay 20, 2024 | finance.yahoo.comInsmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary SessionMay 20, 2024 | prnewswire.comInsmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary SessionMay 17, 2024 | finance.yahoo.comInsider Sale: Chief Medical Officer Martina Flammer Sells Shares of Insmed Inc (INSM)May 17, 2024 | marketbeat.comPrincipal Financial Group Inc. Raises Stock Holdings in Insmed Incorporated (NASDAQ:INSM)Principal Financial Group Inc. raised its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,359,563 shares of the biopharmaceutical company's stock afteMay 16, 2024 | marketbeat.comTruist Financial Reiterates "Buy" Rating for Insmed (NASDAQ:INSM)Truist Financial reaffirmed a "buy" rating and set a $48.00 target price on shares of Insmed in a report on Thursday.May 16, 2024 | insidertrades.comInsider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 5,088 Shares of StockMay 16, 2024 | marketbeat.comQ2 2024 EPS Estimates for Insmed Incorporated Raised by Analyst (NASDAQ:INSM)Insmed Incorporated (NASDAQ:INSM - Free Report) - Research analysts at HC Wainwright increased their Q2 2024 earnings per share estimates for shares of Insmed in a research report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will poMay 15, 2024 | marketbeat.comInsmed Incorporated (NASDAQ:INSM) Insider Sells $129,591.36 in StockInsmed Incorporated (NASDAQ:INSM - Get Free Report) insider John Drayton Wise sold 5,088 shares of the company's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $25.47, for a total value of $129,591.36. Following the completion of the transaction, the insider now directly owns 123,259 shares in the company, valued at $3,139,406.73. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Insmed on Strong TPIP Trial Results and High Anticipation for ASPEN Trial OutcomesMay 14, 2024 | marketbeat.comInsmed (NASDAQ:INSM) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $52.00 price target on shares of Insmed in a research note on Tuesday.May 14, 2024 | marketbeat.comInsmed Incorporated (NASDAQ:INSM) Shares Sold by Swiss National BankSwiss National Bank reduced its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 10.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 269,200 shares of the biopharmaceutical company's sMay 13, 2024 | marketbeat.comMizuho Boosts Insmed (NASDAQ:INSM) Price Target to $36.00Mizuho upped their price objective on Insmed from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Monday.May 13, 2024 | markets.businessinsider.comInsmed (INSM) Receives a Buy from Stifel NicolausMay 12, 2024 | marketbeat.comEssex Investment Management Co. LLC Sells 40,412 Shares of Insmed Incorporated (NASDAQ:INSM)Essex Investment Management Co. LLC cut its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 27.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 108,007 shares of the biopharmaceutical company's stocMay 11, 2024 | finance.yahoo.comInsmed Incorporated (NASDAQ:INSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now INSM Media Mentions By Week INSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INSM News Sentiment▼0.780.78▲Average Medical News Sentiment INSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INSM Articles This Week▼424▲INSM Articles Average Week Get Insmed News Delivered to You Automatically Sign up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TG Therapeutics News Today Schrödinger News Today Sage Therapeutics News Today Emergent BioSolutions News Today FibroGen News Today Viatris News Today United Therapeutics News Today Sarepta Therapeutics News Today Dr. Reddy's Laboratories News Today Catalent News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INSM) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star[Urgent!] Generational Wealth GameplanCrypto 101 MediaCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWrite this ticker symbol down…StocksToTradeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProHe Is Giving Away BitcoinCrypto Swap ProfitsBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
